Fig. 2: TMR–dextran distribution in scLVs and lymph nodes after intracisternal infusion.
From: Increased CSF drainage by non-invasive manipulation of cervical lymphatics
a, Sequence of intracisternal infusion of 1.0 μl TMR–dextran over 1 min into Prox1–GFP mice followed 15, 30, 60 or 120 min later by measurement of TMR–dextran fluorescence in scLVs and draining lymph nodes. b–e, Images (b,d) and measurements (c,e) of TMR–dextran fluorescence in three scLVs that join the smLN. At 30 min after intracisternal infusion, TMR–dextran fluorescence (red arrowheads) is strong in scLV-1 (b), but at 60 min is strong in scLV-1 and scLV-2 (d), yet is essentially absent in scLV-3 at either time point (b,d); measurements support these findings (c,e). Scale bars, 200 μm. Each dot represents one mouse (n = 5 for no infusion, n = 9 for scLV-1, scLV-2 or scLV-3 at 30 min and n = 10 for scLV-1, scLV-2 or scLV-3 at 60 min) from three independent experiments. The error bars indicate mean ± s.e.m. P values were calculated by Kruskal–Wallis test followed by two-tailed Dunn’s multiple comparison post-hoc test. a.u., arbitrary unit. f,g, Images (f) and measurements (g) of temporal changes of TMR–dextran fluorescence in type 1 and type 2 superficial cervical lymph nodes, the dcLN (inset) and the masseter muscle. TMR–dextran fluorescence (red) is strong in all lymph nodes but is not evident in the ptLN (f). Scale bar, 500 μm. The curves show the tracer fluorescence intensity at the four time points. Each dot is the mean value for n = 4–12 mice per group from three independent experiments. The pie chart compares the amounts of tracer fluorescence in the smLN, asmLN and dcLN expressed as the percent of their area under the time-course curve (AUC; g). The error bars indicate mean ± s.e.m. Anatomical positions are indicated in the top left corner. L, lateral; M, medial.
